Lab
G & M Labtesting INC
G & M Labtesting INC was paid $17K by Medicaid between Jun 2023 and Oct 2023, across 16 billing codes. Its largest line is 87801, Infectious agent detection by nucleic acid; amplified probe, multiple organisms — 37% of everything it billed.
33Billing provider infoG & M LABTESTING INC
TUJUNGA, CA 91042
TUJUNGA, CA 91042
33aNPI1457036014assigned 06/20/2023
33bProvider typeClinical Medical Laboratory
28Total paid$17K
24GClaims22,548
24DCodes billed16
24AFirst – last monthJun 2023 – Oct 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#409 of 561
Median peer was paid$222K
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 22,548 | $17K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 37% | 824 | 803 | $6K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 23% | 5,701 | 1,465 | $4K |
| 87481 | 9.6% | 2,025 | 1,337 | $2K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 7.8% | 578 | 575 | $1K |
| 87640 | 2.7% | 1,985 | 1,402 | $475.47 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.6% | 1,991 | 1,403 | $447.48 |
| 87486 | 2.4% | 1,409 | 1,345 | $413.09 | |
| 87581 | 2.4% | 1,410 | 1,346 | $413.09 | |
| 87541 | 2.2% | 1,410 | 1,346 | $381.90 | |
| 87507 | 2.1% | 599 | 590 | $370.47 | |
| 87551 | 1.9% | 812 | 797 | $334.33 | |
| 87561 | 1.5% | 812 | 797 | $260.34 |
4 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOVHANNISYAN, GEVORG (PRESIDENT)